CASE PRESENTATION {#s1}
=================

The patient was a 9-mo-old male born at term via repeat Cesarean section without complications. He had been noted to have right-sided esotropia since 4 mo of age. The patient was referred to a metabolic clinic because of elevated plasma lactate on three occasions (4.3--6.0 mmol/l \[reference range \<2.2 mmol/l\]) at 5 mo of age, but this had normalized (1.3 mmol/l) when seen in metabolic clinic the following month. Pyruvic acid and ammonia were also normal at the time of evaluation, but creatinine kinase was slightly elevated at 150 U/l. He had neurodevelopmental delay evidenced by poor head control and inability to roll over independently at 6 mo of age. The clinician evaluating him at 6 mo of age was unable to fully extend his upper and lower extremities because of hypertonia. (See [Table 1](#FARNAESMCS001776TB1){ref-type="table"}.) The patient had a normal brain magnetic resonance imaging (MRI). At 9 mo of age he was brought to the Rady Children\'s Hospital--San Diego emergency department because of concern over abnormal involuntary movements. He had been developing decreasing responsiveness for 10 d and developed an elevated temperature (102°F) after which the abnormal movements increased in frequency. At the time of admission he had a mildly elevated plasma lactate (3.1 mmol/l). The patient\'s fever resolved within 24 h without an identified infectious etiology. A video electroencephalogram (EEG) at admission to the Pediatric Intensive Care Unit showed evidence of infantile spasms ([Supplemental Data 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001776/-/DC1)). These were treated with high-dose intravenous methylprednisolone, and stopped after 1 d. A brain MRI with spectroscopy and spine MRI were normal. The patient\'s lactate normalized and he had a complete metabolic workup during admission, which was unremarkable ([Supplemental Data 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001776/-/DC1)). The patient and his parents underwent rapid trio whole-genome sequencing (WGS) to determine the spasm etiology. He was discharged on oral steroids and topiramate. One week later he had a repeat video EEG that showed frequent, irregular, short sets of high-voltage, biposterior, Δ waves in the awake state, in the absence of seizures.

###### 

Phenotypic features

  Early infantile epileptic encephalopathy -19                     Proband (II-1)   Comments
  ---------------------------------------------------------------- ---------------- ----------------------------------------------------------------------------------------
  Onset of seizures between ages 8 and 11 months                   Yes              
  Hemiclonic seizures                                              No               
  Tonic-clonic seizures                                            No               
  Focal dyscognitive seizures                                      No               
  Myoclonic seizures                                               No               
  Absence seizures                                                 No               
  Atonic seizures                                                  No               
  Status epilepticus                                               No               
  Febrile sensitivity to seizures                                  Yes              Not febrile seizures
  Intellectual disability                                          Yes              Developmental delay and regression
  EEG with generalized spike-wave discharges or focal discharges   Yes              
  Calcified ependymal nodule on MRI                                No               
  Novel clinical features                                                           
  Infantile spasms                                                 Yes              Not mentioned in OMIM, but reported in one case ([@FARNAESMCS001776C9])
  Esotropia                                                        Yes              
  Infantile muscular hypertonia                                    Yes              Probably secondary to infantile spasms ([@FARNAESMCS001776C4]; [@FARNAESMCS001776C15])

The list of clinical features are based on the OMIM clinical synopsis related to the *GABRA1* gene (\#615744; Epileptic encephalopathy, early infantile, 19). No features on the list were noted in either parent.

EEG, electroencephalogram; MRI, magnetic resonance imaging; OMIM, Online Mendelian Inheritance in Man.

The patient has an unaffected 6-yr-old brother. His parents are both 34 yr old. His maternal and paternal families were from India, with no known consanguinity. There were no other family members with childhood health issues.

TECHNICAL ANALYSIS AND METHODS {#s2}
==============================

A chromosomal microarray (Quest Diagnostics) revealed a likely benign 61-kb interstitial deletion at Chr 2p13.3, which encompasses the genes encoding F-box protein 48 (*FBX048*)*,* aprataxin (*APTX*), and PNKP-like factor (*APLF*).

Four days after consent for trio WGS, DNA was extracted and sequenced using an Illumina HiSeq X with paired 151-nt reads. Sequencing was completed 12 d after consent. Rapid alignment and nucleotide variant calling was performed using the DRAGEN (Edico Genome) hardware and software ([@FARNAESMCS001776C14]). The yield was 176.2, 180.8, and 161.5 Gb for the proband, mother, and father, respectively, resulting in 4,531,103, 4,888,177, and 4,868,923 distinct variant calls, respectively ([Table 2](#FARNAESMCS001776TB2){ref-type="table"}).

###### 

Sequencing data

                                                                   Proband                 Mother                  Father           Units     Reference range
  -------------------------------------------------------- ----------------------- ----------------------- ----------------------- ------- ---------------------
  Sex/trio order                                                 M verified              F verified              M verified                 Trio order verified
  Yield: raw/bulk                                                   176.2                   180.8                   161.5            Gb            \>180
  Percent of mapped                                                98.95%                  98.91%                  98.98%            pct          98--100
  Percent of duplicates                                            11.21%                   9.25%                  10.97%            pct           \<15%
  Yield                                                             154.9                   162.4                   142.3            Gb            \>130
  Insert size: mean ± SD                                          362 ± 128               373 ± 122               360 ± 112          bp          300--480
  Average and median coverage across genome                         46.0                    48.0                    43.0              x            \>40
  Average coverage over OMIM genes                                  47.0                    48.0                    44.0              x            \>40
  Number of OMIM genes with coverage at \<10× (and list)             268                     241                    \>292           ENST        \<2% (282)
  Number of OMIM genes with 100% coverage at ≥10×                   98.1%                   98.3%                   97.9%            pct           \>98%
  Number of OMIM genes with 100% coverage at ≥20×                   93.4%                   97.0%                   92.9%            pct           \>94%
  Number of OMIM genes with 100% coverage at ≥30×                   84.1%                   88.9%                   75.9%            pct           \>80%
  Number of genes with 100% coverage at ≥40×                        31.5%                   37.1%                   15.6%                  
  Variation (VCF) metrics                                                                                                                  
  Number of calls (Total)                                         4,853,103               4,888,177               4,868,923                  2.5--6.0 × 10^6^
  Number of PASS calls                                            4,760,785               4,821,561               4,772,816                  2.5--6.0 × 10^6^
  Number of calls total coding                                     26,917                  27,093                  27,282                     25,000--30,000
  Total number of SNVs                                      3,982,176 \[82.05%\]    4,010,837 \[82.05%\]    3,998,391 \[82.12%\]           
  Total number of Indels                                     870,927 \[17.95%\]      877,340 \[17.95%\]      870,532 \[17.88%\]            
  Hom/Het ratio (in coding regions)                              0.58 (0.61)             0.57 (0.59)             0.58 (0.58)        Ratio        0.5--0.61
  Ti/Tv ratio (in coding regions)                                2.04 (2.94)             2.04 (2.92)             2.04 (2.94)        Ratio     2--2.2 (2.8--3)
  Number of het calls (Number of hom calls)                 3,107,938 (18,498,22)   3,205,140 (1,789,679)   3,128,433 (1,842,666)   Units  
  In silico sample swap check                                       PASS                    PASS                    PASS                      Mendelian test
  Automated upload of VCF to Omicia                                 PASS                    PASS                    PASS                   
  Inform sign-out of analysis-ready state                           PASS                    PASS                    PASS                   
  Detect sample analysis completion state on Omicia                 PASS                    PASS                    PASS                   

SD, standard deviation; OMIM, Online Mendelian Inheritance in Man; VCF, variant call format; SNVs, single-nucleotide variants; Hom/Het, homogeneous/heterogeneous; Ti/Tv, transition/transversion.

Variants were annotated and analyzed in Opal Clinical (Omicia) ([@FARNAESMCS001776C2]). Initially, variants were filtered to retain those with allele frequencies of \<1% in the Exome Variant Server, 1000 Genomes samples, and Exome Aggregation Consortium database (<http://evs.gs.washington.edu/EVS/>. [@FARNAESMCS001776C7]; [@FARNAESMCS001776C8]). A differential diagnostic gene list was built in Phenolyzer ([@FARNAESMCS001776C18]) using Human Phenotype Ontology (HPO) ([@FARNAESMCS001776C11]) and Systematized Nomenclature of Medicine---Clinical Terms (SNOMED-CT([@FARNAESMCS001776C17])). The following codes were used HP:0012469 (infantile spasms, SCTID: 28055006), HP:0001250 (seizures, SCTID: 91175000), HP:0002376 (developmental regression, SCTID: 248290002), HP:0000565 (esotropia, SCTID: 16596007), and HP:0008947 (infantile muscular hypotonia, SCTID: 205294008) (hypotonia was used in the initial evaluation rather than hypertonia due to the prolonged history of poor head control), yielding 1465 genes ([Supplemental Data 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001776/-/DC1)). Research on the optimal number of phenotypic findings to use for creation of a gene list is ongoing at RCIGM; until research is complete we are including all relevant phenotypic findings. Variants were further filtered to retain those mapping to these 1465 genes, yielding 76 proband calls (six homozygous variants, 63 heterozygous inherited variants, and seven heterozygous de novo variants) (see [Supplemental Data 4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001776/-/DC1)). Manual curation revealed one of these as pathogenic (one strong, two moderate, and two supporting criteria) ([Supplemental Data 5, 6](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001776/-/DC1)) by American College of Medical genetics and Genomics (ACMG) guidelines ([@FARNAESMCS001776C16]). However, as per laboratory protocol a designation of "likely" pathogenic was reported, as this nucleotide variant had not previously been reported in any other affected individuals. (See [Table 3](#FARNAESMCS001776TB3){ref-type="table"}.)

###### 

Genomic findings

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       Genomic location                                     HGVS cDNA                HGVS protein   Zygosity       Parent of origin   Variant interpretation
  ---------- ---------------------------------------------------- ------------------------ -------------- -------------- ------------------ ------------------------
  *GABRA1*   NC_000005.10 (on Assembly GRCh38): g.161890983G\>A   NM_000806.5: c.789G\>A   NP_000797.2\   Heterozygous   De novo            Likely pathogenic
                                                                                           p.Met263Ile                                      

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

HGVS, Human Genome Variation Society.

VARIANT INTERPRETATION {#s3}
======================

This patient was heterozygous for a novel likely pathogenic c.789G\>A (p.Met263Ile) variant in the gene encoding the γ-aminobutyric acid (GABA) type A receptor, α1 polypeptide gene (*GABRA1*). GABA is the major inhibitory neurotransmitter in the mammalian brain. It acts at GABA-A receptors, which are ligand-gated chloride channels ([@FARNAESMCS001776C1]). This gene is associated with generalized epilepsy ([@FARNAESMCS001776C12]), juvenile myoclonic epilepsy ([@FARNAESMCS001776C3]), absence epilepsy ([@FARNAESMCS001776C13]), and early infantile epileptic encephalopathy type 19 (EIEE19), which is autosomal dominant, with the onset of recurrent seizures in childhood or adolescence ([@FARNAESMCS001776C5]). Affected individuals can have a wide variety of seizures, including febrile sensitivity to seizures, as in the present case. Esotropia has not previously been associated with EIEE19. *GABRA1* was 538th on the 1465 Phenolyzer gene list (Score 0.002), and had a probability of match to *GABRA1* of 0.016 when the same HPO terms were analyzed in Phenomizer ([@FARNAESMCS001776C10]). *GABRA1* had a haploinsufficiency score of 0.46 and a gene intolerance score of 0.76.

A different variant at the same codon (c.788T\>C, p.Met263Thr) has been previously reported to be likely pathogenic (ClinVar Accession number RCV000187499.2). Furthermore, a missense variant at a different nucleotide in the same codon (c.789G\>C), which resulted in the same amino acid change (p.Met263Ile) as the current patient, was reported as pathogenic in a patient with West syndrome ([@FARNAESMCS001776C9]). The latter patient did not receive a molecular diagnosis until age 9. However, that patient had also shown hypsarrhythmia on EEG at the age of 6 mo. That patient had normal development until the age of 6 mo and then developed developmental delay. That patient also had a normal brain MRI.

The provisional diagnosis was made within 6 h of completion of the sequencing run (see [Supplemental Figure 7](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001776/-/DC1) for current institute workflow). The research protocol under which the trio received rapid WGS was approved by the Food and Drug Administration, and the local Institutional Review Board requires confirmation by a clinically accepted standard before reporting, except in cases of actionable diagnoses in which major morbidity or likelihood of mortality is likely during confirmatory testing. EIEE19 is an actionable diagnosis, but there was very low likelihood of major morbidity or mortality during confirmatory testing. Therefore, the clinical team was notified of the result after Sanger confirmation (day 28).

The diagnosis explained the etiology of the infant\'s seizures, and confirmed that the antiepileptic regimen was appropriate. The infant did well on steroids and topiramate and was gradually weaned off steroids. Several specific GABA-A receptor agonists and modulators have been developed as anticonvulsants and may represent potentially more targeted therapies for patients with refractory EIEE19 than topiramate ([@FARNAESMCS001776C6]).

SUMMARY {#s4}
=======

*GABRA1* p.Met263Ile resulting from c.789G\>A (reported herein) or c.789G\>C (reported previously) appears to be associated with a distinct EIEE19 phenotype that fits the definition of West syndrome (triad of infantile spasms, interictal hypsarrhythmia, and mental retardation): both patients had infantile spasms (clinical diagnosis in the present patient, previous patient with hypsarrhythmia on EEG) between 6 and 9 mo of age ([@FARNAESMCS001776C9]). Both patients had normal MRIs and significant developmental delay. The rapidity of provisional diagnosis by rapid WGS has the potential to enable precision medicine for genetically heterogeneous infantile seizure disorders. A rapid diagnosis may be able to avoid further or unnecessary diagnostic steps. In this case the patient did not have a muscle biopsy to diagnose a mitochondrial disorder and the diagnostic odyssey was brief. If the patient had been referred to us before his extensive metabolic workup, extensive blood tests and laboratory work could have been avoided. The prior reported case with this same protein change had hypsarrhythmia detected at 6 mo of age, but the molecular etiology was not determined until he was 9 yr old. Although the medical therapy was not changed because of sequencing in this case, further workup for treatable causes was avoided. In addition, a firm diagnosis reassured the clinical team and family that the child was on the right therapy.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Sequencing data has been submitted to DNAnexus (<https://platform.dnanexus.com/projects/F670ff00gp1K0Z1x4Yx84VXj/data/WestSyndrome>). Variant was submitted to ClinVar and can be found under accession number SCV000494287.1 (<https://www.ncbi.nlm.nih.gov/clinvar>).
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